🇺🇸 sofosbuvir/ledipasvir in United States

73 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Interaction — 24 reports (32.88%)
  2. Renal Failure Acute — 9 reports (12.33%)
  3. Anaemia — 8 reports (10.96%)
  4. Fatigue — 5 reports (6.85%)
  5. Haemoglobin Decreased — 5 reports (6.85%)
  6. Nausea — 5 reports (6.85%)
  7. Pleural Effusion — 5 reports (6.85%)
  8. Atelectasis — 4 reports (5.48%)
  9. Blood Bilirubin Increased — 4 reports (5.48%)
  10. Dehydration — 4 reports (5.48%)

Source database →

Other Infectious Disease / Virology approved in United States

Frequently asked questions

Is sofosbuvir/ledipasvir approved in United States?

sofosbuvir/ledipasvir does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for sofosbuvir/ledipasvir in United States?

University of Texas Southwestern Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.